Systemic lupus erythematosus and glycation process

AGNIESZKA NOWAK1, BRYGIDA PRZYWARA-CHOWANIEC2, KRYSTYNA TYRPIEŃ-GOLDER1, EWA NOWALANY-KOZIELSKA2

1Department of Chemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland
22nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland

Abstract

Systemic lupus erythematosus (SLE) is a disease of unclear causes, which leads to major immunological disorders. It is characterized by an abnormal immune system activity resulting in the production of autoantibodies. In patients, antibodies targeting normal nuclear components, double-stranded DNA (dsDNA), and phospholipids (cardiolipin) can be detected. The inflammatory process occurs in various tissues and organs, damaging their functions and structure. Disease’s course includes stages of acute symptoms and remissions, and there is no known cure. Pathogenesis and biochemical pathways accompanying systemic lupus erythematosus are widely studied, as existing medication can only bring temporary relief to patients. The recent findings suggest that occurrence of SLE depends on interactions between genetic background of the disease and environmental risk factors such as exposure to tobacco smoke, chemical factors, and hormonal therapy. In the addition, chronic inflammation accompanying SLE disturbs oxidative/antioxidative balance. These processes are linked to intensified advanced glycation end products (AGEs) formation, thus level of AGEs themselves and their receptors (RAGE, sRAGE) are gaining researches attention.

Key words: systemic lupus erythematosus (SLE), sRAGE, advanced glycation, advanced glycation end products, smoking, AGEs.

Epidemiology

The prevalence of lupus varies worldwide, with a noticeable increasing tendency. It might be caused by recognition of new, mild forms of SLE and more accurate diagnostic methods. This tendency is fortunately accompanied by an improvement in survival of affected patients. What draws attention, is the high prevalence of SLE in Italy, Spain, Martinique, and among Afro-Caribbean population of United Kingdom. It is supposed that west Africa women are affected by higher genetic risk of developing SLE [1].

Usually, the disease appears between the ages of 16 to 55-years-old (2/3 of cases) [2], but there is also juvenile or childhood SLE (cSLE) distinguished. A 20% of SLE cases starts before the age of 19, which is often linked to a poor prognosis [3].

Characteristic features of systemic lupus erythematosus

Differential diagnosis of SLE is difficult, with multiple similar disorders that have to be excluded to administer a proper treatment. Therefore, the American College of Rheumatology developed diagnosis criteria, and a diagnosis is confirmed if at least four of them are fulfilled. These criteria can be briefly characterized as follow:

- malar rash,
- discord rash,
- photosensitivity,
- oral or nasopharyngeal ulcerations,
- nonerosive arthritis involving at least 2 joints,
- pleuritis or pericarditis,
- renal disorders manifesting as persistent proteinuria or cellular casts in urine,
- neurologic disorders such as seizures or psychosis,
- hematologic disorders: hemolytic anemia or thrombocytopenia or leucopenia (≥ 2 occasions) or lymphopenia (≥ 2 occasions),
- immunologic disorders: anti-DNA, anti-Sm, or antiphospholipid antibodies presence [4].

These above mentioned symptoms, followed by fatigue, depression, weight loss, and hair loss, are undoubtedly uncomfortable or even life-threatening for patients. Their quality of life is lowered and the disease affects their social life [1, 2]. The activity of disease and damage it causes is measured by the British Isles Lupus Assessment Group

Correspondence: Agnieszka Nowak, MSc, Department of Chemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 41-808 Zabrze, Poland, e-mail: agnieszka00nowak@gmail.com
Submitted: 24.01.2018; Accepted: 23.02.2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International [CC BY-NC-SA 4.0]. License (http://creativecommons.org/licenses/by-nc-sa/4.0/)
BILAG) index and systemic lupus erythematosus disease activity index (SLEDAI) [5, 6].

SLE is undeniably associated with serious renal disorders and is a source of lupus nephritis development. The disease can also affect central nervous system. The autoantibodies can bind to murine and human N-methyl-D-aspartate receptors, leading to neurons apoptosis. The damage causes a wide range of symptoms. Unfortunately, methods of monitoring lupus in central nervous system are insufficient [1].

Furthermore, SLE manifests in cardiovascular system due to intensified atherosclerosis. A higher prevalence of cardiovascular disease is observed among lupus patients [1, 7]. De Leeuw et al. discovered a positive correlation between skin accumulation of advanced glycation products and intima-media thickness (its value is an indicator of atherosclerosis). Glycation process is therefore probably linked to acceleration of changes occurring in SLE patients’ blood vessels [8]. Therefore, SLE can be described as a risk factor in cardiovascular disorders. Additionally, SLE patients are at higher risk of non-Hodgkin lymphoma development [1].

**Risk factors**

Recent findings suggest that occurrence of SLE depends on interactions between environmental risk factors and genetic background of the disease. Epigenetic modifications of genes are likely to be involved [9].

Systemic lupus erythematosus is 6-10 times more common among females than males, usually affecting women during childbearing age [2, 9]. This phenomenon is believed to be associated with female sex hormones activity and X chromosome (even the inactive one) [1, 9]. The change in levels of dehydroepiandrosterone, estradiol, pro lactin, and testosterone was discovered in women with SLE [9]. It was observed that hormone replacement therapy (HRT) and the use of oral contraceptive hormones influenced higher risk of SLE. However, studies results have been ambiguous regarding the connection of exogenous estrogen usage with the presence of SLE and symptoms relapses (flares) [1, 9]. A link between early menarche, early (or surgical) menopause, endometriosis, and increased risk of SLE also suggests important role of estrogen in pathogenesis [9, 10].

Drugs intake may cause drug-induced lupus erythematosus (DILE). There are over one hundred drugs known for resveratrol content [9]. On the contrary, moderate alcohol intake is accompanied by lowered risk of SLE presence. The protective influence of alcoholic drinks might be caused by their content of substances that counteract inflammation. Most positive effects are achieved with wine consumption, which is known for resveratrol content [9].

**Genetic background**

Several genes may be important in SLE development and pathogenesis. This include overexpression of multiple unique isoforms of common interferon regulatory factor 5 (IRF5) and the type I interferon pathway. Another genetic factor is a single nucleotide polymorphism (SNP) discovered in the programmed cell death 1 gene (PDCD1). This small inheritable change in nucleotides is associated with SLE in patients [1].

Polymorphisms of C-reactive protein (CRP) also drive researchers attention. SLE, while being an autoimmune disease, does not lead to an increased level of CRP. There are two haplotypes of CRP, 2 and 4, which lower the ex-
pression of CRP. What is more, CRP 4 haplotype is linked to SLE’s typical feature: autoantibodies production [1].

**Pathogenesis**

SLE is a disease characterized by multifactorial etiology, where environmental stimuli might influence epigenetic changes or induce SLE because of existing genetic susceptibility. Multiple defects (e.g. in T cells signaling pathways) were described in immunological system of patients [1].

Autoantibodies (e.g. anti-DNA, anti-La, antinuclear, antiphospholipid, anti-RNP, anti-Ro, anti-Sm) appear years before the development of the disease is recognizable. However, anti-DNA, anti-Sm, and anti-RNP may appear shortly before the diagnosis [1]. The key element of pathogenesis is immune complexes (IC) formation. They are deposited in skin and kidneys, damaging their functions [12].

What causes the development of autoantibodies is still under study. A defect of apoptotic cells clearance may cause intracellular compounds being left to be collected by macrophages. These internal cell elements might be recognized as autoantigens and later presented to T and B cells. This triggers an immune response against own tissues [1]. Another cause of autoaggression might be a molecular mimicry, where endogenous and exogenous antigens similarity triggers immunological response [9, 13]. When such a mimicry occurs, epitopes can amplify and diversify through process described as “epitope spreading” to form a wide range of autoantibodies [13].

Widely recognized implication of chronic inflammation is the state of increased oxidative stress and distorted oxidative/antioxidative balance [14].

**Advanced glycation products**

Both in living organisms and foodstuffs, a spontaneous glycation of proteins occurs. Reaction of reducing sugars and amino acids is called the Maillard reaction, and causes formation of various Maillard reaction products (MRPs). In vivo sugars can similarly react with proteins, with lipids, and nucleic acids, to produce advanced glycation end products (AGEs). These compounds are more abundant in inflamed tissues, and inflammatory process is associated with oxidative stress. Reference data show a link between oxidative stress, AGEs formation, and autoimmune diseases such as SLE [7].

Advanced glycation end products examined in patients included pentosidine, carboxymethyllysine (CML), and its homologue carboxyethyllysine (CEL), which are presented in Table 1 [7, 15]. AGEs are markers of glycation occurrence in organisms. They can affect tissues both structurally (e.g. through cross-linking with proteins they damage extracellular matrix) and functionally (e.g. due to interactions with receptors) [7].

Accumulation of AGEs in skin of SLE patients was confirmed [7, 8]. There is also a positive correlation between AGEs accumulation and duration of the disease, but skin autofluorescence does not correlate with antiphospholipid autoantibodies presence [8]. The increased presence of AGEs in blood of patients is still discussed. Nienhuis et al. indicated that there were no significant differences between SLE patients and controls in blood plasma levels of two specific AGEs such as CML and CEL. AGEs levels did not correlate with CRP levels. Authors suggested that advanced glycation end products were mostly accumulated in tissues rather than in plasma proteins [7]. This point of view is supported by study conducted by Vytášek et al. Authors observed no significant difference between healthy controls and SLE patients’ blood levels of CEL and antigen binding to mononuclear antibody 103-E3 (unknown product of protein and ribose reaction) [16]. Also, pentosidine level was not increased in blood of SLE patients examined as a group by Rodríguez-García et al. Noteworthy, some patients showed remarkably high pentosidine levels and in all subjects, fructosamine serum level was increased [16].

Table 1. Available data on levels of various AGEs (advanced glycation products) in SLE (systemic lupus erythematosus) patients compared to controls: total AGEs level, pentosidine, CML (carboxymethyllysine), CEL (carboxyethyllysine), unknown product of protein and ribose reaction

| Examined compounds | Results (compared to control) | Examined material | Reference |
|--------------------|--------------------------------|------------------|-----------|
| AGEs               | Increased in SLE patients      | Skin (autofluorescence) | 7, 8      |
|                    | Increased in SLE patients with active disease | Positive correlation with disease activity | Blood plasma | 15 |
| Pentosidine        | No difference                  | Blood serum      | 17        |
| CML                | No difference                  | Blood plasma     | 7         |
| CEL                | No difference                  | Blood plasma     | 7         |
|                    | No difference                  | Blood serum      | 16        |
| Protein and ribose reaction product | No difference | Blood serum | 16        |
and noted a positive correlation between SLEDAI score and AGEs concentration [15].

**Receptor for advanced glycation end products**

Receptor for AGEs comes in transmembrane (RAGE) and circulating (soluble – sRAGE; endogenous secretory – esRAGE) forms. It is a glycoprotein that belongs to immunoglobulin super family and it binds with multiple ligands, including advanced glycation end products, high mobility group protein B1 (HMGB-1), β-amyloid, amphoterin, and S100/calgranulin family members [7, 12, 18].

If the HMGB-1 is not bound by sRAGE, an interaction between RAGE and HMGB-1 occurs easier, which results in pro-inflammatory response [12].

SLE activity correlates with S100A8/A9 level in serum. S100A8/A9 belongs to previously mentioned S100 proteins family that exhibits various functions and may be excreted by cells during inflammation. The level of S100A12 does not differ between SLE patients and healthy subjects. However, levels of S100A8/A9 and S100A12 correlate with cardiovascular risk in SLE patients [12, 19, 20].

The ligands seems to be mostly related to inflammation, hyperglycation, and cell stress processes; the expression of receptor itself is directly related to inflammation [21]. S100A12 induces lymphocytes proliferation and cytokine release through binding with RAGE and it causes the immune response to amplify. S100/calgranulin and RAGE levels are increased in inflammation areas in laboratory animals. The inflammation symptoms can be attenuated by administration of sRAGE or antibodies against S100/calgranulin and RAGE [18].

It was also observed that RAGE receptor can bind non-specifically with nucleic acids and compounds with sugar-phosphate backbones lacking nucleotide bases through electrostatic attraction. It plays a key role in self-tolerance to extracellular DNA and RNA. It promotes intracellular uptake and allows TLR9 (Toll-like receptor 9; nucleic acid immune receptor) to interact with nucleic acids. Membrane RAGE deficiency prevents the immune response to DNA. RAGE is expressed by endothelial and vascular smooth muscle cells, macrophages, neutrophils, and T cells. Notably, RAGE is highly expressed in lung epithelia, so the role of tobacco smoke exposure and silica exposure seems to be even more clear and important in SLE development [21]. sRAGE can also bind to the RAGE, blocking its functions [12].

Binding AGES to RAGE leads to enhanced expression of molecules involved in inflammation, adhesion, and RAGE itself. Also, the expression of RAGE is enhanced by TNF-α (tumor necrosis factor α). The soluble form is believed to be a decoy receptor that prevents interactions between transmembrane form and AGES. sRAGE seems to have a protective effects on organisms, with low levels of the receptor increasing the risk of all-cause death. It remains unknown if SLE patients have autoantibodies against RAGE and sRAGE, but the sRAGE functions are insufficient in these subjects [7]. A decreased amount of

| Table 2. Available data on levels of sRAGE in SLE patients compared to healthy controls |
|-----------------------------------------------|-----------------|-----------------|
| Observations                                  | Material examined | Reference       |
| Increased level of sRAGE in SLE patients compared to healthy controls | Blood serum | 7               |
| Positive correlation with anti-dsDNA antibodies’ level |                  |                 |
| Increased level of sRAGE in SLE patients compared to healthy controls | Blood serum | 22              |
| Decreased level of sRAGE in SLE patients compared to healthy controls | Blood serum | 3               |
| Decreased level of sRAGE in SLE patients compared to healthy controls | Blood plasma | 12              |
| Higher level of sRAGE in SLE patients who undergone long-term treatment compared to patients treated shorter than a month | Blood plasma | 20              |
| No difference of sRAGE level between treated and untreated SLE patients |                  |                 |
| Increased level of sRAGE in SLE patients with serositis and cutaneous manifestation of the disease | Blood plasma | 20              |
| Decreased level of sRAGE in SLE patients compared to healthy controls | Blood plasma | 24              |
| Higher level of sRAGE in SLE patients who undergone long-term treatment compared to patients treated shorter than a month | Blood plasma | 15              |
| No difference of sRAGE level between treated and untreated SLE patients |                  |                 |
| Increased level of sRAGE in SLE patients with rash and serositis |                  |                 |
| Decreased level of sRAGE in SLE patients compared to healthy controls | Blood plasma | 23              |
| No correlation between sRAGE level and disease activity |                  |                 |
| Decreased level of sRAGE in SLE patients compared to healthy controls | Blood plasma | 15              |
| Negative correlation between sRAGE level and SLEDAI score |                  |                 |
| Decreased level of sRAGE in SLE patients with active disease compared to healthy controls | Blood plasma | 23              |
sRAGE was detected in Sjogren’s syndrome, showing a possible link between SLE and visual disturbance [12].

Contradictory data about the level of sRAGE in SLE patients are summarized in Table 2. Nienhuis et al. reported that the concentration of sRAGE is increased in lupus patients serum [7]. Also, Nashaat Abou-Raya et al. discovered higher concentration of sRAGE in blood plasma of lupus patients. In their study, sRAGE levels positively correlated with SLEDAI score [22].

On the other hand, more references describe decrease of sRAGE level in SLE patients’ blood plasma compared to healthy controls [12, 15, 20]. Similar findings apply to cSLE patients [3]. Yu et al. noted a decrease in plasma sRAGE level in patients with active SLE and at the same time, an increased level of full-length form of RAGE receptor present on monocytes’ surface [23]. It is believed that enlarged amount of receptor’s ligands in patients’ blood leads to intensified consumption of sRAGE. Of note, treated and untreated SLE patients have similar levels of sRAGE, and subjects who received long-term medication have a higher concentration of the soluble receptor than subjects who undergo short-term treatment (< 1 month). What is more, short administration of medication causes a significant fall in the level of sRAGE, compared to the control and long-term treated subjects. Authors of both studies suggest the receptor has a different role in initial and progressed stage of the disease [12, 20]. A study focused on patients displaying antiphospholipid antibodies (APA) or antiphospholipid antibody syndrome (APS) involved SLE patients. Both groups, SLE+APA and SLE+APS patients showed a decrease of sRAGE level in blood plasma compared to healthy controls. What is more, subjects diagnosed with APS, but without lupus, had the level of sRAGE no different from control [24].

The level of the soluble receptor displays a relation with some blood parameters including leucocytes and lymphocytes amounts, neutrophils and monocytes amounts, and C4 complement component [3, 12, 20]. This fact suggest the soluble receptor is associated with inflammation and leucocytes recruitment [12]. However, the level of the soluble receptor may not correlate with autoantibodies presence [20].

RAGE and sRAGE have ability to interact with themselves and multiple ligands. Also, their ligands can interact with one another [21]. Receptors and ligands are directly related to immunological response, infection, and protein glycation. These processes increase oxidative stress in organism. Oxidation and RAGE actions with additional sRAGE deficiency can cause formation of neoepitopes, which induce formation of auto-antibodies.

Conclusions

Although diagnostic criteria of systematic lupus erythematosus are defined and many factors of the pathophysiology of SLE have been recognized, there are still no definite premises for the proper causes of this disease. Some of advanced glycation end products correlated with the progression of this disease, that is why further researches are necessary to determine their role in the pathogenesis of SLE.

Acknowledgments

The work was supported by the KNW-1-038/K/7/0 project of the Medical University of Silesia in Katowice.

The authors declare no conflict of interest.

References

1. D’Cruz PD, Khamashta MA, Hughes GRV (2007): Systemic lupus erythematosus. The Lancet 369: 587-596.
2. Szczeklik A, Gajewski P (2011): Choroby wewnętrzne. Medycyna Praktyczna, Kraków.
3. Bobek D, Grčević D, Kovačić N, et al. (2014): The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatric Rheumatol Online J 12: 50.
4. 1997 update of the 1982 American College of Rheumatology revised criteria for classification of systemic lupus erythematosus. https://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20Revised.pdf. Updated February 2015.
5. Hay EM, Bacon PA, Gordon C, et al. (1993): The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86: 447-458.
6. Bombardier C, Gladman DD, Urowitz MB, et al. (1992): Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-640.
7. Nienhuis HL, de Leeuw K, Bijzet J, et al. (2008): Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford) 47: 1554-1558.
8. de Leeuw K, Graaff R, de Vries R, et al. (2007): Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (Oxford) 46: 1551-1556.
9. Barbhaiya M, Costenbader KH (2016): Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol 28: 497-505.
10. Lisnevskaiia L, Murphy G, Isenberg D (2014): Systemic lupus erythematosus. Lancer 384: 1878-1888.
11. Freemen MM, King Jr TE, Criswell LA (2006): Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 65: 581-584.
12. Bayoumy N, El-Shabrawi M, Nada H (2013): A soluble receptor for advanced glycation end product levels in patients with systemic lupus erythematosus. Arch Rheumatol 208: 101-108.
13. Kurien BT, Scofield H (2008): Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 7: 567-573.
14. Taysi S, Gul M, Sari RA, et al. (2002): Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 40: 684-688.
15. Chen DY, Chen YM, Lin CC, et al. (2015): The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset Still’s disease. BMC Musculoskelet Disord 16: 111.
16. Vytášek R, Šedová L, Víflím V (2010): Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord 11: 83.
17. Rodríguez-García J, Requena JR, Rodríguez-Segade S (1998): Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem 44: 250-255.
18. Schmidt AM, Yan SD, Yan SF, Stern DM (2001): The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955.
19. Tydén H, Lood C, Gullstrand B, et al. (2013): Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford) 52: 2048-2055.
20. Ma CY, Ma JL, Jiao YL, et al. (2012): The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand J Immunol 75: 614-622.
21. Sirois CM, Jin T, Miller AL, et al. (2013): RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med 210: 2447-2463.
22. Abou-Rayya AN, Nabi Kamel MA, Ghani Sayed EA, Hamid El-Sharkawy AA (2016): The plasma level of soluble receptor for advanced glycation end products in systemic lupus erythematosus patients and its relation to disease activity. AJM 52: 151-157.
23. Yu SL, Wong CK, Szeto CC, et al. (2015): Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. Lupus 24: 675-686.
24. Tang KT, Hsieh TY, Chao YH, et al. (2017): Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients. PLoS One 12: e0178404.